EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints

Didem Torumkuney, Balaji Veeraraghavan, Niranjan Patil, Mary Dias, Geeti Maheshwari, Bhaskar Narayan Chaudhuri, Ujjwayini Ray, Stephen Hawser, Subhashri Kundu, Anand Manoharan

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Didem Torumkuney und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Unit, GSK, London, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Haemophilus influenzae, Streptococcus pneumoniae, Drug Resistance, Bacterial. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, Ashfield MedComms, Inizio company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Antibiotic susceptibility determination of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae were collected from India (2018–21).

Methods

MICs were determined by CLSI broth microdilution; susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

Results

S. pneumoniae (n = 177) and H. influenzae (n = 171) isolates were collected from four hospital laboratories and two private laboratories in India. Only 41.2% pneumococci were penicillin susceptible by CLSI oral/EUCAST low-dose breakpoints, but 94.4% were susceptible by EUCAST high-dose/CLSI IV breakpoints. Good activity (≥89.8%, CLSI or PK/PD breakpoints) was observed for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, ceftriaxone, levofloxacin, and moxifloxacin. Cefdinir and second-generation cephalosporins were less active (27.7%–64.4%). Tetracyclines, macrolides and trimethoprim/sulfamethoxazole showed poor activity (18.6%–31.1%). EUCAST breakpoints indicated >90% susceptibility to high-dose ceftriaxone and penicillin, moxifloxacin and high-dose levofloxacin. Lower susceptibility to other cephalosporins and aminopenicillins was observed with EUCAST versus CLSI or PK/PD breakpoints. Most H. influenzae isolates (91.8%) were β-lactamase negative; 13 and 5 were β-lactamase-negative ampicillin-resistant following EUCAST and CLSI criteria, respectively. Antibiotic susceptibility was ≥84.8% (CLSI) for all antibiotics except trimethoprim/sulfamethoxazole (23.4%). Susceptibility by EUCAST was similar, except for cefuroxime (oral) with no susceptible isolates versus 95.3% by CLSI and ≤29.8% versus ≥85.4% for fluoroquinolones.

Conclusions

Some therapeutic options against S. pneumoniae and H. influenzae from CA-RTI in India remain, but only ceftriaxone covers both bacterial species using both guidelines. Continued surveillance of antibiotic susceptibility is important to monitor changes and trends in susceptibilities and for guiding empiric therapy of CA-RTIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHaemophilus influenzaeStreptococcus pneumoniaeDrug Resistance, BacterialHumansIndiaMicrobial Sensitivity TestsCommunity-Acquired InfectionsRespiratory Tract InfectionsHaemophilus InfectionsAdultPneumococcal InfectionsMaleChildMiddle AgedChild, PreschoolFemaleInfantAdolescentYoung Adult

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Infectious Diseases Research Unit, GSK, London, UK.
  • Department of Clinical Microbiology, Christian Medical College, Vellore, India.
  • Microbiology and Infectious Molecular Biology, Metropolis Healthcare Private Limited, Vidyavihar West, Mumbai, India.
  • Department of Microbiology and Division of Infectious Diseases, St John's Medical College Hospital, Bangalore, India.
  • Department of Microbiology and Molecular Sciences, Toprani Advanced Lab Systems, Vadodara, India.
  • Microbiology Research Center LTD, Peerless Hospital, Kolkata, India.

Förderung

  • GSK
  • Ashfield MedComms
  • Inizio company

Zitieren

APA

Torumkuney, D., Veeraraghavan, B., Patil, N., Dias, M., Maheshwari, G., Chaudhuri, B. N., Ray, U., Hawser, S., Kundu, S., & Manoharan, A. (2025). Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf285

Vancouver

Torumkuney D, Veeraraghavan B, Patil N, Dias M, Maheshwari G, Chaudhuri BN, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf285

BibTeX
@article{Torumkuney2025,
  author = {Torumkuney, Didem and Veeraraghavan, Balaji and Patil, Niranjan and Dias, Mary and Maheshwari, Geeti and Chaudhuri, Bhaskar Narayan and Ray, Ujjwayini and Hawser, Stephen and Kundu, Subhashri and Manoharan, Anand},
  title = {Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf285}
}
Kostenlos starten →